Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy

While promising, PD-L1 expression on tumor tissues as assessed by immunohistochemistry has been shown to be an imperfect biomarker that only applies to a limited number of cancers, whereas many patients with PD-L1-negative tumors still respond to anti-PD-(L)1 immunotherapy. Recent studies using pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Tao, Denman, Desirée, Bacot, Silvia M., Feldman, Gerald M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138337/
https://www.ncbi.nlm.nih.gov/pubmed/35625917
http://dx.doi.org/10.3390/biomedicines10051181

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138337/
https://www.ncbi.nlm.nih.gov/pubmed/35625917
http://dx.doi.org/10.3390/biomedicines10051181

Ejemplares similares